DT
Deep Track Capital, LP
Deep Track Capital, LP · Investor
1Y performance ⓘ
+165%
AUM (13F)
$6.1B
# of Holdings
61
3Y performance ⓘ
+142%
vs S&P 500 ⓘ
+78%
Updated
Mar 31
Deep Track Capital, LP's Deep Track Capital, LP holds 61 U.S.-equity positions worth $6.1B (SEC 13F, Q1 2026). Top positions: Spdr Series Trust 20.9%, Guardant Health, Inc. Common Stock 5.0%, Immunovant, Inc. Common Stock 4.7%. 13F-replication return is +142% over 3 years (+78 pts vs the S&P 500) — a replicated, non-audited figure.
Holdings
| Stock | % of portfolio | Shares | Value | Latest activity | Avg buy price | Current price | Date |
|---|---|---|---|---|---|---|---|
| XBI Spdr Series Trust | 20.9% | 10.0M | $1.3B | — | $121.93 | $147.01 (+21%) | 2026-03-31 |
| GH Guardant Health, Inc. Common Stock | 5.0% | 3.3M | $308M | ▲ 19% (+538K) | $38.27 | $161.99 (+323%) | 2026-03-31 |
| IMVT Immunovant, Inc. Common Stock | 4.7% | 11.5M | $286M | — | $22.78 | $38.62 (+70%) | 2026-03-31 |
| TARS Tarsus Pharmaceuticals, Inc. Common Stock | 4.1% | 3.6M | $253M | ▲ 20% (+596K) | $56.51 | $59.04 (+4%) | 2026-03-31 |
| PCVX Vaxcyte, Inc. Common Stock | 4.1% | 4.3M | $250M | ▲ 7.5% (+300K) | $39.08 | $54.08 (+38%) | 2026-03-31 |
| GPCR Structure Therapeutics Inc | 3.4% | 4.3M | $206M | ▲ 4.1% (+168K) | $27.22 | $48.04 (+76%) | 2026-03-31 |
| AXSM Axsome Therapeutics, Inc | 3.0% | 1.1M | $186M | ▼ 4.3% (−50K) | $102.40 | $217.99 (+113%) | 2026-03-31 |
| APLSUSD Apellis Pharmaceuticals Inc | 3.0% | 4.5M | $182M | ▼ 42% (−3.2M) | $58.78 | — (−32%) | 2026-03-31 |
| OCUL Ocular Therapeutix, Inc. | 2.7% | 19.7M | $167M | ▲ 144% (+11.6M) | $7.42 | $8.17 (+10%) | 2026-03-31 |
| VERA Vera Therapeutics, Inc. Class A Common Stock | 2.7% | 4.1M | $165M | ▲ 46% (+1.3M) | $47.38 | $32.10 (−32%) | 2026-03-31 |
| ALMS Alumis Inc. Common Stock | 2.4% | 6.8M | $149M | NEW (+6.8M) | $22.03 | $28.25 (+28%) | 2026-03-31 |
| IONS Ionis Pharmaceuticals, Inc. Common Stock | 2.4% | 1.9M | $146M | ▲ 15% (+250K) | $39.85 | $51.77 (+30%) | 2026-03-31 |
| NUVL Nuvalent, Inc. Class A Common Stock | 2.3% | 1.4M | $141M | NEW (+1.4M) | $96.69 | — (+6%) | 2026-03-31 |
| ALKS Alkermes Inc. plc | 2.1% | 3.6M | $127M | ▲ 80% (+1.6M) | $31.33 | $48.99 (+56%) | 2026-03-31 |
| CNTA Centessa Pharmaceuticals Plc | 2.0% | 3.2M | $125M | ▲ 58% (+1.2M) | $28.98 | — (+37%) | 2026-03-31 |
| MLTX MoonLake Immunotherapeutics Class A Ordinary Shares | 1.9% | 6.4M | $119M | ▲ 39% (+1.8M) | $15.35 | $18.44 (+20%) | 2026-03-31 |
| MAZE Maze Therapeutics, Inc. Common Stock | 1.7% | 3.5M | $104M | ▼ 18% (−769K) | $13.34 | $26.92 (+102%) | 2026-03-31 |
| ORKA Oruka Therapeutics, Inc. Common Stock | 1.6% | 2.0M | $100M | ▼ 5.9% (−127K) | $16.94 | $96.51 (+470%) | 2026-03-31 |
| NRIX Nurix Therapeutics, Inc. Common stock | 1.6% | 6.3M | $98M | ▼ 9.8% (−691K) | $12.82 | $23.21 (+81%) | 2026-03-31 |
| GMAB Genmab A/s | 1.6% | 3.7M | $98M | NEW (+3.7M) | $26.05 | $28.87 (+11%) | 2026-03-31 |
| CYTK Cytokinetics Inc. | 1.5% | 1.4M | $91M | ▼ 59% (−2.0M) | $47.24 | $77.13 (+63%) | 2026-03-31 |
| GRAL GRAIL, Inc. Common Stock | 1.4% | 1.7M | $89M | ▲ 68% (+700K) | $71.81 | $68.56 (−5%) | 2026-03-31 |
| LBRX LB Pharmaceuticals Inc Common Stock | 1.4% | 3.4M | $83M | — | $15.79 | $40.08 (+154%) | 2026-03-31 |
| MBX MBX Biosciences, Inc. Common Stock | 1.3% | 2.8M | $82M | ▼ 15% (−492K) | $23.64 | $65.93 (+179%) | 2026-03-31 |
| BCAX Bicara Therapeutics Inc. Common Stock | 1.3% | 4.1M | $81M | ▲ 55% (+1.4M) | $19.00 | $27.10 (+43%) | 2026-03-31 |
| CMPS Compass Pathways Plc | 1.1% | 12.2M | $67M | ▲ 66% (+4.8M) | $4.04 | $11.35 (+181%) | 2026-03-31 |
| BMRN BioMarin Pharmaceuticals Inc | 1.1% | 1.1M | $65M | ▼ 50% (−1.1M) | $59.37 | $60.02 (+1%) | 2026-03-31 |
| BBIO BridgeBio Pharma, Inc. Common Stock | 1.0% | 841K | $62M | ▲ 3.9% (+31K) | $38.72 | $80.09 (+107%) | 2026-03-31 |
| IMCR Immunocore Hldgs Plc | 0.9% | 1.9M | $58M | ▼ 3.6% (−72K) | $30.47 | $33.81 (+11%) | 2026-03-31 |
| TNGX Tango Therapeutics, Inc. | 0.9% | 2.8M | $58M | ▲ 12% (+295K) | $9.91 | $27.18 (+174%) | 2026-03-31 |
| DFTX Definium Therapeutics, Inc. Common Shares | 0.9% | 3.0M | $57M | NEW (+3.0M) | $18.90 | $43.52 (+130%) | 2026-03-31 |
| 430 Terns Pharmaceuticals Inc | 0.9% | 1.1M | $57M | ▲ 40% (+305K) | $8.75 | — (+503%) | 2026-03-31 |
| GERN Geron Corp | 0.8% | 31.7M | $47M | ▼ 2.4% (−791K) | $1.63 | $1.29 (−21%) | 2026-03-31 |
| ANIP ANI Pharmaceuticals, Inc. | 0.8% | 600K | $46M | ▲ 26% (+122K) | $63.10 | $79.24 (+26%) | 2026-03-31 |
| CRMD CorMedix Inc. | 0.7% | 6.3M | $43M | ▲ 19% (+1.0M) | $10.86 | $7.53 (−31%) | 2026-03-31 |
| ATAI AtaiBeckley Inc. Common Stock | 0.7% | 12.0M | $42M | NEW (+12.0M) | $3.54 | $7.18 (+103%) | 2026-03-31 |
| CLDX Celldex Therapeutics, Inc | 0.7% | 1.3M | $41M | ▼ 32% (−617K) | $23.63 | $38.06 (+61%) | 2026-03-31 |
| COGT Cogent Biosciences, Inc. Common Stock | 0.6% | 1.0M | $38M | ▲ 121% (+547K) | $28.27 | $38.93 (+38%) | 2026-03-31 |
| CRVS Corvus Pharmaceuticals, Inc. | 0.6% | 2.5M | $36M | NEW (+2.5M) | $14.63 | $13.26 (−9%) | 2026-03-31 |
| DYN Dyne Therapeutics, Inc. Common Stock | 0.6% | 2.0M | $36M | ▼ 25% (−650K) | $20.63 | $25.18 (+22%) | 2026-03-31 |
| ACRS Aclaris Therapeutics, Inc. | 0.6% | 9.3M | $35M | NEW (+9.3M) | $4.54 | $5.20 (+14%) | 2026-03-31 |
| MANE Veradermics, Incorporated | 0.5% | 500K | $32M | NEW (+500K) | $63.15 | $105.00 (+66%) | 2026-03-31 |
| VSTM Verastem, Inc. | 0.5% | 5.7M | $30M | — | $7.72 | $5.80 (−25%) | 2026-03-31 |
| VRDN Viridian Therapeutics, Inc. Common Stock | 0.5% | 1.4M | $27M | ▼ 45% (−1.1M) | $18.30 | $18.92 (+3%) | 2026-03-31 |
| XFOR X4 Pharmaceuticals, Inc. Common Stock | 0.4% | 6.3M | $26M | ▲ 26% (+1.3M) | $3.92 | $3.98 (+1%) | 2026-03-31 |
| SLDB Solid Biosciences Inc. Common Stock | 0.4% | 3.6M | $26M | NEW (+3.6M) | $7.20 | $8.06 (+12%) | 2026-03-31 |
| ENTA Enanta Pharmaceuticals, Inc | 0.4% | 2.0M | $25M | — | $15.77 | $12.60 (−20%) | 2026-03-31 |
| APGE Apogee Therapeutics, Inc. Common Stock | 0.4% | 285K | $24M | NEW (+285K) | $21.30 | $134.09 (+530%) | 2026-03-31 |
| KURA Kura Oncology, Inc. | 0.3% | 2.6M | $21M | NEW (+2.6M) | $16.76 | $9.01 (−46%) | 2026-03-31 |
| IPSC Century Therapeutics, Inc. Common Stock | 0.3% | 9.5M | $21M | NEW (+9.5M) | $2.33 | $2.02 (−13%) | 2026-03-31 |
Showing top 50 of 61 holdings by value.
FAQ ▾
What are Deep Track Capital, LP's largest holdings?
As of the latest 13F: Spdr Series Trust 20.9%, Guardant Health, Inc. Common Stock 5.0%, Immunovant, Inc. Common Stock 4.7%, Tarsus Pharmaceuticals, Inc. Common Stock 4.1%, Vaxcyte, Inc. Common Stock 4.1%.
How big is Deep Track Capital, LP's 13F portfolio?
$6.1B across 61 disclosed U.S.-equity positions.
What is Deep Track Capital, LP's 3-year performance?
+142% (13F-replication, price return), +78 pts vs the S&P 500. Not an audited fund return.
Where does this data come from?
U.S. SEC Form 13F-HR institutional holdings filings.
Sourced from SEC Form 13F-HR filings · Not investment advice ▾
Data as of 2026-03-31 · Methodology
13F-replication (price return, filing-date based) — not an audited fund return.
Published by WealthFile · Not investment advice.
Latest activity = change vs. the prior 13F. Avg buy price = est. entry over the trailing 3 years (gain = vs. latest price). Returns are 13F-replication, not audited fund returns. Sourced from SEC 13F filings.